Acute coronary syndromes

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as...

Dr. Andrés Rodríguez - 11 June, 2025

Acute coronary syndromes

EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients

Primary percutaneous coronary intervention (PCI) with stent implantation is the recommended treatment for ST-segment elevation myocardial infarction...

Dr. Andrés Rodríguez - 29 May, 2025

Acute coronary syndromes

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

While dual antiplatelet therapy (DAPT) has long been the standard treatment for managing patients with acute coronary...

Dr. Andrés Rodríguez - 26 May, 2025

Acute coronary syndromes

EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

Patients with extensive acute myocardial infarctions may develop cardiogenic shock, which has been associated with marked contractile...

Dr. Omar Tupayachi - 22 May, 2025

Acute coronary syndromes

EuroPCR 2025 | 10-Year Follow-up of DANAMI-3-PRIMULTI: Complete vs. Culprit-Only Revascularization in STEMI with Multivessel Disease

The DANAMI-3-PRIMULTI trial included 627 patients with ST-elevation myocardial infarction (STEMI) and multivessel coronary artery disease (MVD),...

solaci - 22 May, 2025

Acute coronary syndromes

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Courtesy of Dr. Juan Manuel Pérez. Spontaneous left main dissection in an uncommon, and potentially life-threatening, cause of...

Dr. Juan Manuel Pérez - 5 May, 2025

Acute coronary syndromes

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary...

Dr. Omar Tupayachi - 29 April, 2025

Acute coronary syndromes

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this...

Dr. Omar Tupayachi - 29 April, 2025

Acute coronary syndromes

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

EuroPCR 2025 | DANAMI-3-DEFER: 10-Year Results of Deferred vs. Conventional Stenting in STEMI Patients

EuroPCR 2025 | 4D-ACS Study: One-Month Dual Antiplatelet Therapy Followed by Low-Dose Prasugrel Monotherapy

EuroPCR 2025 | Multivessel PCI in Cardiogenic Shock: A Substudy from the DanGer Shock

EuroPCR 2025 | 10-Year Follow-up of DANAMI-3-PRIMULTI: Complete vs. Culprit-Only Revascularization in STEMI with Multivessel Disease

Spontaneous Left Main Dissection: Clinical Characteristics, management and Outcomes

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Últimas Noticias

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Is it really necessary to monitor all patients after TAVR?

Is it really necessary to monitor all patients after TAVR?

Noticias Institucionales

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

Accesos